Literature DB >> 31760356

Patient-reported outcome measures after treatment for prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata).

Mary Nguyen-Nielsen1, Henrik Møller2, Anne Tjønneland3, Michael Borre4.   

Abstract

PURPOSE: This study compares the side effects of active surveillance, prostatectomy, radiation with or without adjuvant endocrine therapy, watchful waiting, and palliative therapy on patient-reported outcomes in a nationwide, population-based cohort of Danish men with prostate cancer.
METHODS: A total of 15,465 participants completed questionnaires over a 5 year period (2011-2016). Condition-specific quality of life, focusing on urinary function, bowel incontinence, sexual function, and hormonal symptoms were investigated using the validated EPIC-26 questionnaire at diagnosis, 1 year- and 3- year follow-up. Patients were identified from the Danish Prostate Cancer Registry with data-linked to several national healthcare registries. Longitudinal analysis with linear mixed effects models were fitted to compare changes over time on quality of life symptom scores for five treatment modalities, adjusting for age, clinical TNM stage, PSA value, Gleason score, Charlson Comorbidity score, education, disposable income, and urbanization measured at time of prostate cancer diagnosis.
RESULTS: There was a more than10-point decrease in mean scores across all symptom domains at 1-year follow-up. Thereafter mean scores for all symptom domains improved marginally and remained relatively unchanged at 3-year follow-up. Prostatectomy had the greatest negative effect on sexual function and urinary incontinence. Overall quality of life was most adversely affected by sexual function, regardless of treatment modality.
CONCLUSION: Clinical interventions for improving symptoms should focus particularly on the first year after prostate cancer diagnosis. Greater emphasis on improving sexual function should be practiced in clinical and rehabilitative care, since this area has the single greatest impact on symptom-specific QoL after primary treatment for prostate cancer.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Patient-reported outcomes; Prostate cancer; Quality of life

Mesh:

Year:  2019        PMID: 31760356     DOI: 10.1016/j.canep.2019.101623

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  5 in total

1.  Association between the baseline frailty and quality of life in patients with prostate cancer (FRAQ-PC study).

Authors:  Tomoko Hamaya; Shingo Hatakeyama; Masaki Momota; Takuma Narita; Hiromichi Iwamura; Yuta Kojima; Itsuto Hamano; Naoki Fujita; Teppei Okamoto; Kyo Togashi; Tohru Yoneyama; Hayato Yamamoto; Takahiro Yoneyama; Yasuhiro Hashimoto; Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2020-10-16       Impact factor: 3.402

2.  Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer.

Authors:  Roman O Kowalchuk; David Hillman; Thomas B Daniels; Carlos E Vargas; Jean-Claude M Rwigema; William W Wong; Bradley J Stish; Amylou C Dueck; Richard Choo
Journal:  Clin Transl Radiat Oncol       Date:  2021-09-15

3.  Comparison of Clinical Outcomes of Radical Prostatectomy versus IMRT with Long-Term Hormone Therapy for Relatively Young Patients with High- to Very High-Risk Localized Prostate Cancer.

Authors:  Hung-Jen Shih; Shyh-Chyi Chang; Chia-Hao Hsu; Yi-Chu Lin; Chu-Hsuan Hung; Szu-Yuan Wu
Journal:  Cancers (Basel)       Date:  2021-11-28       Impact factor: 6.639

4.  Application Effect of Bladder Function Training Combined with Kangaiping Pills on Permanent Bladder Stoma after Radical Prostatectomy.

Authors:  Kefu Sha; Yue Zhao; Deng Yang; Zhaoxia Song; Mingjun Zhao; Jieqing Gao; Tiejun Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-24       Impact factor: 2.629

5.  Competing risk of the specific mortality among Asian-American patients with prostate cancer: a surveillance, epidemiology, and end results analysis.

Authors:  Di Wu; Yaming Yang; Mingjuan Jiang; Ruizhi Yao
Journal:  BMC Urol       Date:  2022-03-24       Impact factor: 2.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.